New data on the heart benefit of an obesity drug from Novo Nordisk increases the chances of a pay-off for it and rival Eli Lilly, which have spent a record amount on U.S. lobbying to win government backing for the drugs, analysts and experts said. U.S. law classifies weight-loss treatments as lifestyle drugs and bars Medicare from paying for them. Novo and Eli Lilly have spent nearly $1.3 million this year lobbying the U.S. Congress on obesity and specifically on a bill reintroduced in July that would allow the Medicare health plan to reimburse these medicines.
Obesity drug data could boost companies case for US coverage, analysts say reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
By Elissa Welle NEW YORK (Reuters) - A new study is raising fresh questions about the value of breast cancer screening in older women, finding that th.
A new study is raising fresh questions about the value of breast cancer screening in older women, finding that those 70 and older who underwent mammograms were more apt to be diagnosed with tumors posing no threat to their health than those who did not screen. The study by researchers at Yale Medical School, published on Monday in the journal Annals of Internal Medicine, tracked 54,635 U.S. women 70 and older who received a mammogram - an X-ray of the breast - in 2002. Women who opted for continued screening were compared to those who chose not to be screened.